Clinical Trial

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Study acronym: ITP
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-08 -> 2026-12 2026-07-25
minor Completion pushed: 2026-08 -> 2027-01 2026-07-25
Trial Details
NCT Number NCT07059000
Lead Sponsor Kedrion S.p.A.
Conditions Chronic Primary Immune Thrombocytopenia (ITP)
Enrollment 40 participants
Start Date 2025-08-13
Primary Completion 2026-12 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06